DrugCite
Search

IDARUBICIN

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Idarubicin Adverse Events Reported to the FDA Over Time

How are Idarubicin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Idarubicin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Idarubicin is flagged as the suspect drug causing the adverse event.

Most Common Idarubicin Adverse Events Reported to the FDA

What are the most common Idarubicin adverse events reported to the FDA?

Febrile Neutropenia
232 (3.02%)
Sepsis
172 (2.24%)
Pyrexia
113 (1.47%)
Pneumonia
107 (1.39%)
Septic Shock
106 (1.38%)
Respiratory Failure
103 (1.34%)
Acute Myeloid Leukaemia
99 (1.29%)
Neutropenia
96 (1.25%)
Pancytopenia
93 (1.21%)
Multi-organ Failure
92 (1.2%)
Infection
78 (1.02%)
Show More Show More
Diarrhoea
73 (.95%)
Thrombocytopenia
64 (.83%)
Myelodysplastic Syndrome
62 (.81%)
Platelet Count Decreased
60 (.78%)
Renal Failure
60 (.78%)
Bone Marrow Failure
59 (.77%)
Mucosal Inflammation
59 (.77%)
Renal Failure Acute
54 (.7%)
Dyspnoea
53 (.69%)
Anaemia
51 (.66%)
Death
50 (.65%)
Aplasia
47 (.61%)
Pleural Effusion
47 (.61%)
Haemorrhage
46 (.6%)
Vomiting
46 (.6%)
Hypotension
45 (.59%)
Atrial Fibrillation
41 (.53%)
Neutropenic Colitis
40 (.52%)
Hepatic Function Abnormal
39 (.51%)
Drug Toxicity
38 (.5%)
White Blood Cell Count Decreased
38 (.5%)
Stomatitis
37 (.48%)
Alanine Aminotransferase Increased
35 (.46%)
Neutropenic Sepsis
35 (.46%)
Haemorrhage Intracranial
34 (.44%)
Tumour Lysis Syndrome
34 (.44%)
Lung Infection
33 (.43%)
Cytogenetic Abnormality
32 (.42%)
Pulmonary Haemorrhage
32 (.42%)
Rash
32 (.42%)
Aspartate Aminotransferase Increase...
31 (.4%)
Cardiac Arrest
31 (.4%)
Hyperbilirubinaemia
31 (.4%)
Nausea
31 (.4%)
Acute Respiratory Distress Syndrome
30 (.39%)
Disseminated Intravascular Coagulat...
30 (.39%)
Hypoxia
29 (.38%)
Ascites
28 (.36%)
Condition Aggravated
28 (.36%)
Hepatotoxicity
28 (.36%)
Hyperpyrexia
28 (.36%)
Neutrophil Count Decreased
28 (.36%)
Cardiac Failure
27 (.35%)
Disease Progression
27 (.35%)
Cerebral Haemorrhage
26 (.34%)
Abdominal Pain
25 (.33%)
Encephalopathy
25 (.33%)
Fungal Infection
25 (.33%)
Hypokalaemia
25 (.33%)
Rhabdomyolysis
25 (.33%)
Bronchopulmonary Aspergillosis
24 (.31%)
Drug Ineffective
24 (.31%)
Febrile Bone Marrow Aplasia
24 (.31%)
General Physical Health Deteriorati...
24 (.31%)
Renal Impairment
24 (.31%)
Aspergillosis
23 (.3%)
Asthenia
23 (.3%)
Haemoglobin Decreased
23 (.3%)
Ileus
23 (.3%)
Metabolic Acidosis
23 (.3%)
Blood Bilirubin Increased
22 (.29%)
Blood Culture Positive
22 (.29%)
Interstitial Lung Disease
22 (.29%)
Pericarditis
22 (.29%)
Venoocclusive Liver Disease
22 (.29%)
Caecitis
21 (.27%)
Cellulitis
20 (.26%)
Colitis
20 (.26%)
Drug Exposure During Pregnancy
20 (.26%)
Haemodialysis
20 (.26%)
Lung Infiltration
20 (.26%)
Pneumonia Fungal
20 (.26%)
Zygomycosis
20 (.26%)
Blood Creatinine Increased
19 (.25%)
Enterococcal Infection
19 (.25%)
Haemoptysis
19 (.25%)
Leukopenia
19 (.25%)
Pulmonary Oedema
19 (.25%)
Staphylococcal Infection
19 (.25%)
Dermatitis Bullous
18 (.23%)
Graft Versus Host Disease
18 (.23%)
Hepatic Failure
18 (.23%)
Oedema
18 (.23%)
Pseudomonal Sepsis
18 (.23%)
Respiratory Distress
18 (.23%)
Staphylococcal Sepsis
18 (.23%)
Stem Cell Transplant
18 (.23%)
Acute Myeloid Leukaemia Recurrent
17 (.22%)
Caesarean Section
17 (.22%)
Enterococcal Sepsis
17 (.22%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Idarubicin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Idarubicin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Idarubicin

What are the most common Idarubicin adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Idarubicin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Idarubicin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Idarubicin According to Those Reporting Adverse Events

Why are people taking Idarubicin, according to those reporting adverse events to the FDA?

Acute Myeloid Leukaemia
926
Acute Promyelocytic Leukaemia
172
Acute Lymphocytic Leukaemia
74
Acute Leukaemia
52
Myelodysplastic Syndrome
48
Multiple Myeloma
39
Show More Show More
Acute Myeloid Leukaemia Recurrent
34
Chemotherapy
31
Product Used For Unknown Indication
21
Drug Use For Unknown Indication
20
Acute Monocytic Leukaemia
20
Non-hodgkins Lymphoma
17
Acute Myelomonocytic Leukaemia
17
Haematological Malignancy
17
Lymphoma
15
Myeloid Leukaemia
12
Diffuse Large B-cell Lymphoma
11
Bone Marrow Conditioning Regimen
9
Stem Cell Transplant
9
Plasmacytoma
8
Lymphocytic Leukaemia
7
Neoplasm Malignant
7
Leukaemia
7
Ill-defined Disorder
7
Chronic Myeloid Leukaemia
5
T-cell Lymphoma
5
Adult T-cell Lymphoma/leukaemia Ref...
4
Chloroma
4
Chronic Lymphocytic Leukaemia
4
Anaemia Haemolytic Autoimmune
4
Leukaemia Cutis
4
Retinoblastoma
4
Acute Megakaryocytic Leukaemia
3
Bone Marrow Transplant
3
B Precursor Type Acute Leukaemia
3
Adult T-cell Lymphoma/leukaemia
3
Hodgkins Disease
2
Retinoblastoma Bilateral
2
Chronic Myelomonocytic Leukaemia
2
Acute Biphenotypic Leukaemia
2
Mucosal Inflammation
2
B-cell Lymphoma
2
T-cell Type Acute Leukaemia
2
Cord Blood Transplant Therapy
2
Allogenic Bone Marrow Transplantati...
2
Stomatitis
2
Myelofibrosis
2
Acute Lymphocytic Leukaemia Recurre...
2
Chronic Myeloid Leukaemia Transform...
2
Breast Cancer Metastatic
1
Blast Cell Count Increased
1

Drug Labels

LabelLabelerEffective
Idamycin PfsPharmacia and Upjohn Company15-JUN-10
Idarubicin HydrochlorideSandoz Inc06-APR-11
Idarubicin HydrochlorideAPP Pharmaceuticals, LLC24-APR-12
Idarubicin HydrochlorideTeva Parenteral Medicines, Inc13-AUG-12
Idarubicin HydrochlorideAmneal-Agila, LLC28-DEC-12

Idarubicin Case Reports

What Idarubicin safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Idarubicin. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Idarubicin.